Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use ENJAYMO safely and effectively. See full prescribing information for ENJAYMO. ENJAYMO ® (sutimlimab-jome) injection, for intravenous use Initial U.S. Approval: 2022
Medication labelWhy this: Advisory · dailymed-prescription
Cold Agglutinin Disease ENJAYMO (sutimlimab-jome) is indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD).
- generic_name
- sutimlimab-jome
- product_names
- sutimlimab-jome
- ndc
- 80203-347, 80203-347-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en